All patients (n = 361) | Standard dose (n = 280) | Low dose (n = 81) | p value | |
---|---|---|---|---|
Total follow-up time (months), median (min, max, IQR) | 19 (1, 177; 46) | 14.5 (1, 127; 27) | 56 (1, 177; 59) | < 0.0001 |
Total cumulative RTX exposure (g), median (min, max, IQR) | 38 (2, 254; 72) | 28 (2, 254; 52) | 90 (2, 246; 78) | < 0.0001 |
Disease flares | 22 (6.3%) | 16 (5.9%) | 6 (7.5%) | 0.599 |
Reasons for RTX discontinuation | ||||
Failuresa | 105 (59.3%) | 94 (63.6%) | 11 (37.9%) | < 0.0001 |
Adverse events as stop reasonb (all) | 34 (19.2%) | 25 (16.9%) | 9 (31.0%) | 0.131 |
Infections | 18 (10.2%) | 14 (9.5%) | 4 (13.8%) | 0.711 |
Other adverse events | 16 (9.0%) | 11 (7.4%) | 5 (17.2%) | 0.183 |
Other reasonsc | 38 (21.5%) | 29 (19.5%) | 9 (31.1%) | 0.002 |